Drugs / Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated)
Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05918939 | Sep 2022 → Aug 2023 | COVID-19 | Dr. Soetomo General Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05508477 | Jun 2022 → Mar 2023 | COVID-19 | Dr. Soetomo General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05918939 ↗ |
| Modality | Vaccine | “Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) is an inactivated vaccine made of SARS-CoV-2 virus isolated from a patient in Surabaya” NCT05508477 ↗ |
| Route | Intramuscular | “The vaccine will be administered intramuscularly.” NCT05918939 ↗ |